Baseline characteristics for patients enrolled on lenalidomide monotherapy and lenalidomide and (rhu-EPO) combined therapy
| . | Monotherapy (n = 39) . | Combination therapy (n = 23) . |
|---|---|---|
| Mean age, y | 70.8 | 70.1 |
| Sex | ||
| Male | 28 (71.8%) | 18 (78.3%) |
| Female | 11 (28.2%) | 5 (21.7%) |
| ECOG performance status | ||
| 0 | 7 (17.9%) | 6 (26.1%) |
| 1 | 31 (79.5) | 17 (73.9%) |
| 2 | 1 (2.6%) | 0 |
| Median duration of MDS, y (range) | 1.9 (0.4-13.3) | 3.2 |
| Median RBC transfusion burden for 4 weeks, n (range) | 4 (2.0-10.0) | |
| MDS FAB subtype, n (%) | ||
| RA | 11 (28%) | 7 (30%) |
| RARS | 15 (38.5%) | 7 (30%) |
| RCMD | 4 (10.0%) | 3 (13%) |
| RAEB | 8 (21%) | 5 (22%) |
| CMML | 1 (2.5%) | 1 (4.3%) |
| Cytogenetics, n (%) | ||
| Non-del(5q) | 32 (82%) | 19 (83%) |
| del(5q) | 7 (18%) | 4 (17%) |
| IPSS, n (%) | ||
| Low risk | 18 (46.2%) | 11 (47.8%) |
| Intermediate-1 risk | 21 (53.8%) | 12 (52.2%) |
| Serum EPO level | ||
| Mean, IU (SD) | 955 (1652) | 600 (921) |
| Patients > 500 IU, n (%) | 15/36 (39%) | 7/23 (30%) |
| . | Monotherapy (n = 39) . | Combination therapy (n = 23) . |
|---|---|---|
| Mean age, y | 70.8 | 70.1 |
| Sex | ||
| Male | 28 (71.8%) | 18 (78.3%) |
| Female | 11 (28.2%) | 5 (21.7%) |
| ECOG performance status | ||
| 0 | 7 (17.9%) | 6 (26.1%) |
| 1 | 31 (79.5) | 17 (73.9%) |
| 2 | 1 (2.6%) | 0 |
| Median duration of MDS, y (range) | 1.9 (0.4-13.3) | 3.2 |
| Median RBC transfusion burden for 4 weeks, n (range) | 4 (2.0-10.0) | |
| MDS FAB subtype, n (%) | ||
| RA | 11 (28%) | 7 (30%) |
| RARS | 15 (38.5%) | 7 (30%) |
| RCMD | 4 (10.0%) | 3 (13%) |
| RAEB | 8 (21%) | 5 (22%) |
| CMML | 1 (2.5%) | 1 (4.3%) |
| Cytogenetics, n (%) | ||
| Non-del(5q) | 32 (82%) | 19 (83%) |
| del(5q) | 7 (18%) | 4 (17%) |
| IPSS, n (%) | ||
| Low risk | 18 (46.2%) | 11 (47.8%) |
| Intermediate-1 risk | 21 (53.8%) | 12 (52.2%) |
| Serum EPO level | ||
| Mean, IU (SD) | 955 (1652) | 600 (921) |
| Patients > 500 IU, n (%) | 15/36 (39%) | 7/23 (30%) |
CMML indicates chronic myelomonocytic leukemia; FAB, French-American-British system; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ring sideroblasts; and CMD, refractory cytopenia with multilineage dysplasia.